# Bicara Therapeutics Inc.: financial statements, quarterly

BCAX · Nasdaq · CIK 2023658 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bcax.md) · [Financials](/companies/bcax/financials.md) · [Filings](/companies/bcax/filings.md) · [Insiders](/companies/bcax/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bcax/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [6.9](/filings/0002023658-24-000002.md) | [10.5 d](/filings/0002023658-25-000012.md) | [12.0](/filings/0002023658-25-000039.md) | [15.8](/filings/0002023658-25-000098.md) | [15.9](/filings/0002023658-25-000109.md) | [19.9 d](/filings/0002023658-25-000012.md) | [34.3](/filings/0002023658-25-000039.md) | [24.8](/filings/0002023658-25-000098.md) | [33.0](/filings/0002023658-25-000109.md) | not reported | not reported | not reported |
| Operating income | $m | [(9.5)](/filings/0002023658-24-000002.md) | [(13.7) d](/filings/0002023658-25-000012.md) | [(15.4)](/filings/0002023658-25-000039.md) | [(19.8)](/filings/0002023658-25-000098.md) | [(20.6)](/filings/0002023658-25-000109.md) | [(26.6) d](/filings/0001628280-26-022010.md) | [(41.8)](/filings/0001628280-26-033429.md) | [(32.0)](/filings/0001628280-26-055765.md) | [(40.7)](/filings/0002023658-25-000109.md) | [(41.1) d](/filings/0001628280-26-022010.md) | [(60.2)](/filings/0001628280-26-033429.md) | [(60.0)](/filings/0001628280-26-055765.md) |
| Income tax | $m | [0.0](/filings/0002023658-24-000002.md) | [0.0 d](/filings/0002023658-25-000012.md) | [0.0](/filings/0002023658-25-000039.md) | [0.0](/filings/0002023658-25-000098.md) | [0.0](/filings/0002023658-25-000109.md) | [0.2 d](/filings/0001628280-26-022010.md) | [0.1](/filings/0001628280-26-033429.md) | [0.1](/filings/0001628280-26-055765.md) | [0.0](/filings/0002023658-25-000109.md) | [0.1 d](/filings/0001628280-26-022010.md) | [0.1](/filings/0001628280-26-033429.md) | [0.1](/filings/0001628280-26-055765.md) |
| Net income | $m | [(22.8)](/filings/0002023658-24-000002.md) | [(12.4) d](/filings/0002023658-25-000012.md) | [(12.5)](/filings/0002023658-25-000109.md) | [(17.0)](/filings/0002023658-25-000109.md) | [(17.5)](/filings/0002023658-25-000109.md) | [(21.0) d](/filings/0001628280-26-022010.md) | [(36.8)](/filings/0001628280-26-055765.md) | [(27.4)](/filings/0001628280-26-055765.md) | [(36.3)](/filings/0002023658-25-000109.md) | [(37.4) d](/filings/0001628280-26-022010.md) | [(56.2)](/filings/0001628280-26-055765.md) | [(55.4)](/filings/0001628280-26-055765.md) |
| Diluted EPS | $ per share | [(38.23)](/filings/0002023658-24-000002.md) | not reported | [(18.94)](/filings/0002023658-25-000039.md) | [(19.01)](/filings/0002023658-25-000098.md) | [(1.60)](/filings/0002023658-25-000109.md) | not reported | [(0.68)](/filings/0001628280-26-033429.md) | [(0.50)](/filings/0001628280-26-055765.md) | [(0.67)](/filings/0002023658-25-000109.md) | not reported | [(0.93)](/filings/0001628280-26-033429.md) | [(0.82)](/filings/0001628280-26-055765.md) |
| Basic EPS | $ per share | [(38.23)](/filings/0002023658-24-000002.md) | not reported | [(18.94)](/filings/0002023658-25-000039.md) | [(19.01)](/filings/0002023658-25-000098.md) | [(1.60)](/filings/0002023658-25-000109.md) | not reported | [(0.68)](/filings/0001628280-26-033429.md) | [(0.50)](/filings/0001628280-26-055765.md) | [(0.67)](/filings/0002023658-25-000109.md) | not reported | [(0.93)](/filings/0001628280-26-033429.md) | [(0.82)](/filings/0001628280-26-055765.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [230](/filings/0002023658-25-000012.md) | not reported | not reported | [521](/filings/0002023658-24-000002.md) | [490](/filings/0001628280-26-022010.md) | [462](/filings/0002023658-25-000039.md) | [437](/filings/0002023658-25-000098.md) | [172](/filings/0002023658-25-000109.md) | [96.7](/filings/0001628280-26-055765.md) | [323](/filings/0001628280-26-033429.md) | [96.6](/filings/0001628280-26-055765.md) |
| Current assets | $m | not reported | [231](/filings/0002023658-25-000012.md) | not reported | not reported | [522](/filings/0002023658-24-000002.md) | [503](/filings/0001628280-26-022010.md) | [471](/filings/0002023658-25-000039.md) | [444](/filings/0002023658-25-000098.md) | [297](/filings/0002023658-25-000109.md) | [422](/filings/0001628280-26-055765.md) | [545](/filings/0001628280-26-033429.md) | [504](/filings/0001628280-26-055765.md) |
| Total assets | $m | not reported | [234](/filings/0002023658-25-000012.md) | not reported | not reported | [524](/filings/0002023658-24-000002.md) | [510](/filings/0001628280-26-022010.md) | [478](/filings/0002023658-25-000039.md) | [454](/filings/0002023658-25-000098.md) | [425](/filings/0002023658-25-000109.md) | [431](/filings/0001628280-26-055765.md) | [554](/filings/0001628280-26-033429.md) | [512](/filings/0001628280-26-055765.md) |
| Current liabilities | $m | not reported | [15.1](/filings/0002023658-25-000012.md) | not reported | not reported | [14.5](/filings/0002023658-24-000002.md) | [18.0](/filings/0001628280-26-022010.md) | [19.1](/filings/0002023658-25-000039.md) | [17.2](/filings/0002023658-25-000098.md) | [21.0](/filings/0002023658-25-000109.md) | [28.9](/filings/0001628280-26-055765.md) | [39.3](/filings/0001628280-26-033429.md) | [43.5](/filings/0001628280-26-055765.md) |
| Total liabilities | $m | not reported | [15.5](/filings/0002023658-25-000012.md) | not reported | not reported | [14.6](/filings/0002023658-24-000002.md) | [18.1](/filings/0001628280-26-022010.md) | [19.1](/filings/0002023658-25-000039.md) | [18.4](/filings/0002023658-25-000098.md) | [21.9](/filings/0002023658-25-000109.md) | [29.5](/filings/0001628280-26-055765.md) | [39.6](/filings/0001628280-26-033429.md) | [43.5](/filings/0001628280-26-055765.md) |
| Shareholders' equity | $m | [(137)](/filings/0002023658-24-000002.md) | [(149)](/filings/0001628280-26-022010.md) | [(160)](/filings/0002023658-25-000109.md) | [(175)](/filings/0002023658-25-000109.md) | [510](/filings/0002023658-25-000109.md) | [492](/filings/0001628280-26-055765.md) | [459](/filings/0001628280-26-055765.md) | [435](/filings/0001628280-26-055765.md) | [403](/filings/0002023658-25-000109.md) | [401](/filings/0001628280-26-055765.md) | [514](/filings/0001628280-26-055765.md) | [469](/filings/0001628280-26-055765.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.0) d](/filings/0002023658-25-000012.md) | [(14.6)](/filings/0002023658-25-000039.md) | [(12.9) d](/filings/0002023658-25-000098.md) | [(17.2) d](/filings/0002023658-25-000109.md) | [(30.0) d](/filings/0001628280-26-022010.md) | [(28.1)](/filings/0001628280-26-033429.md) | [(25.6) d](/filings/0001628280-26-055765.md) | [(29.2) d](/filings/0002023658-25-000109.md) | [(23.9) d](/filings/0001628280-26-022010.md) | [(37.5)](/filings/0001628280-26-033429.md) | [(44.2) d](/filings/0001628280-26-055765.md) |
| Capital expenditure | $m | [0.4 d](/filings/0002023658-25-000012.md) | [0.0](/filings/0002023658-25-000039.md) | [0.0 d](/filings/0002023658-25-000098.md) | [0.0 d](/filings/0002023658-25-000109.md) | [0.0 d](/filings/0001628280-26-022010.md) | [0.0](/filings/0001628280-26-033429.md) | [0.0 d](/filings/0001628280-26-055765.md) | [0.0 d](/filings/0002023658-25-000109.md) | [0.2 d](/filings/0001628280-26-022010.md) | [0.1](/filings/0001628280-26-033429.md) | [0.1 d](/filings/0001628280-26-055765.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.6](/filings/0002023658-24-000002.md) | [0.7](/filings/0002023658-25-000039.md) | [0.9](/filings/0002023658-25-000098.md) | [10.9](/filings/0002023658-25-000109.md) | [54.5](/filings/0001628280-26-033429.md) | [54.5](/filings/0001628280-26-055765.md) | [54.6](/filings/0002023658-25-000109.md) | [60.7](/filings/0001628280-26-033429.md) | [67.9](/filings/0001628280-26-055765.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 66,172,934 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001628280-26-055765.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.